Home

main

Illumina Ventures

Illumina Ventures is the leader in genomics and precision health investing. We are building the ecosystem and translating investment into innovation as we accelerate the impact on human health.

About Us
slider-portfolio
Portfolio Spotlight

Measuring previously undetectable structural changes in biomolecules.

Read More

“RedShiftBio’s mission is to deploy the power of novel analytical tools in life science research and biopharmaceutical drug development, tackling previously unsolvable problems in structural biology.”

Julien Bradley, CEO

Making single cell sequencing more efficient and accessible.

Read More

“Single-cell RNA sequencing is a critical tool in understanding complex biological processes. Fluent Biosciences is significantly advancing the field with its scalability, cost-effectiveness, and high-throughput capabilities.”

Brian Mckernan, CEO

Rapidly advancing cell-based therapeutics by harnessing patients’ B cells.

Read More

“Walking Fish has a mission to deliver life-saving, cell-based therapies to patients in need by engineering B-cells to produce therapeutic proteins. This can be applied to multiple diseases, including genetic protein deficiencies, cancer, and infectious diseases.”

Rusty Williams, Co-founder, Chairman and CEO

Taking the next steps in gene editing.

Read More

“Arbor is focused on bringing novel gene editing approaches to patients with severe genetic diseases. For many genetic diseases, gene editing is one of the best ways to create a life changing therapy.”

Devyn Smith, CEO

slider-news

Latest News

Tagomics Raises £6.7m to Improve Disease Diagnosis

2/29/2024 Read More

Stilla Technologies closes $26.5M Series C financing to accelerate commercialization of its digital PCR platform – expands leadership team

2/23/2024 Read More